| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Articles |
From the Masonic Medical Research Laboratory (D.H., H.-B.M., E.B., Y.W., R.P., J.M.C., A.G., G.D.P., C.A.), Utica, NY; Cardiology Department (M.S.), University of Louisville, Louisville, Ky; Heart Failure Research Center (T.T.K.), Academic Medical Center Amsterdam, The Netherlands; Department of Pharmacology and Pharmacotherapy (A.V.), University of Szeged, Szeged, Hungary; and Division for Cardiovascular Pharmacology (A.V.), Hungarian Academy of Sciences, Szeged, Hungary.
Correspondence to Charles Antzelevitch, PhD, Masonic Medical Research Laboratory, 2150 Bleecker St, Utica, NY. E-mail ca{at}mmrl.edu
Received October 15, 2008; accepted April 20, 2009.
Background— Brugada syndrome, characterized by ST-segment elevation in the right precordial ECG leads and the development of life-threatening ventricular arrhythmias, has been associated with mutations in 6 different genes. We identify and characterize a mutation in a new gene.
Methods and Results— A 64-year-old white male displayed a type 1 ST-segment elevation in V1 and V2 during procainamide challenge. Polymerase chain reaction-based direct sequencing was performed using a candidate gene approach. A missense mutation (L10P) was detected in exon 1 of SCN3B, the β3 subunit of the cardiac sodium channel, but not in any other gene known to be associated with Brugada syndrome or in 296 controls. Wild-type (WT) and mutant genes were expressed in TSA201 cells and studied using whole-cell patch-clamp techniques. Coexpression of SCN5A/WT+SCN1B/WT+SCN3B/L10P resulted in an 82.6% decrease in peak sodium current density, accelerated inactivation, slowed reactivation, and a –9.6-mV shift of half-inactivation voltage compared with SCN5A/WT+SCN1B/WT+SCN3B/WT. Confocal microscopy revealed that SCN5A/WT channels tagged with green fluorescent protein are localized to the cell surface when coexpressed with WT SCN1B and SCN3B but remain trapped in intracellular organelles when coexpressed with SCN1B/WT and SCN3B/L10P. Western blot analysis confirmed the presence of NaVβ3 in human ventricular myocardium.
Conclusions— Our results provide support for the hypothesis that mutations in SCN3B can lead to loss of transport and functional expression of the hNav1.5 protein, leading to reduction in sodium channel current and clinical manifestation of a Brugada phenotype.
Key Words: Brugada syndrome arrhythmia ion channels SCN3B protein trafficking
This article has been cited by other articles:
![]() |
C. R. Valdivia, A. Medeiros-Domingo, B. Ye, W.-K. Shen, T. J. Algiers, M. J. Ackerman, and J. C. Makielski Loss-of-function mutation of the SCN3B-encoded sodium channel {beta}3 subunit associated with a case of idiopathic ventricular fibrillation Cardiovasc Res, January 20, 2010; (2010): cvp417v2 - cvp417. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Amin, E. A.A. de Groot, J. M. Ruijter, A. A.M. Wilde, and H. L. Tan Exercise-Induced ECG Changes in Brugada Syndrome Circ Arrhythm Electrophysiol, October 1, 2009; 2(5): 531 - 539. [Abstract] [Full Text] [PDF] |
||||
|
Home | Subscriptions | Archives | Feedback | Authors | Help | Circulation Journals Home | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |